Exhibit 99.1 There can be no assurance that the process will result in any such transaction. VYNE's Board of Directors has not set a timetable for the strategic review process. VYNE does not intend to provide updates until the Board approves a specific action or otherwise determines that disclosure is appropriate or required. The Company has engaged LifeSci Capital as a financial advisor to assist in the strategic review process. Pipeline Overview VYN202, an oral small molecule BD2-selective BET inhibitor: ...